Literature DB >> 1970357

In vitro and in vivo antitumoral activity of free, and encapsulated taxol.

M H Bartoli1, M Boitard, H Fessi, H Beriel, J P Devissaguet, F Picot, F Puisieux.   

Abstract

The anti-tumoral activity of taxol encapsulated either in liposomes or in nanocapsules was compared with that of free taxol, using the P388 and L1210 leukaemia test systems. The in vitro inhibition of cell growth was measured after 48 h and 96 h exposure to various concentrations of taxol. With P388 cells, the inhibitory activities of the three forms of the drug were similar. With the L1210 cells, however, the concentrations required for a 50 per cent inhibition of cell growth (IC50) after 48 h exposure to the drug were greater for nanocapsules than for liposomes or free taxol, the values being 0.060, 0.043 and 0.035 micrograms ml-1, respectively. However, a greater efficiency of nanocapsules was observed after 96 h exposure. Using cytomorphometric analysis, no difference was found between L1210 cells treated either with free or encapsulated taxol. In vivo, mice bearing P388 leukaemia, and treated either with taxol solubilized with 5 per cent DMSO + 5 per cent cremophor in saline solution, or with taxol encapsulated in liposomes (IP daily dose of 12.5 mg Kg-1 body weight x 4 days) showed ILS values of 65.8% and 67.9% respectively. Nanocapsules proved to be toxic, apparently due to their composition: this problem is currently under investigation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1970357     DOI: 10.3109/02652049009021832

Source DB:  PubMed          Journal:  J Microencapsul        ISSN: 0265-2048            Impact factor:   3.142


  9 in total

1.  Development of paclitaxel-TyroSpheres for topical skin treatment.

Authors:  Brian E Kilfoyle; Larisa Sheihet; Zheng Zhang; Marissa Laohoo; Joachim Kohn; Bozena B Michniak-Kohn
Journal:  J Control Release       Date:  2012-06-23       Impact factor: 9.776

Review 2.  Progress in the development of alternative pharmaceutical formulations of taxanes.

Authors:  B Nuijen; M Bouma; J H Schellens; J H Beijnen
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

3.  Pharmacokinetics of paclitaxel-containing liposomes in rats.

Authors:  Gerald J Fetterly; Robert M Straubinger
Journal:  AAPS PharmSci       Date:  2003-11-21

Review 4.  Liposomes as carriers of cancer chemotherapy. Current status and future prospects.

Authors:  S Kim
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

5.  Evaluation of biodistribution and anti-tumor effect of a dimeric RGD peptide-paclitaxel conjugate in mice with breast cancer.

Authors:  Qizhen Cao; Zi-Bo Li; Kai Chen; Zhanhong Wu; Lina He; Nouri Neamati; Xiaoyuan Chen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-03-29       Impact factor: 9.236

Review 6.  A critical review of lipid-based nanoparticles for taxane delivery.

Authors:  Lan Feng; Russell J Mumper
Journal:  Cancer Lett       Date:  2012-07-13       Impact factor: 8.679

7.  A mixed micellar formulation suitable for the parenteral administration of taxol.

Authors:  H Alkan-Onyuksel; S Ramakrishnan; H B Chai; J M Pezzuto
Journal:  Pharm Res       Date:  1994-02       Impact factor: 4.200

8.  Designing Paclitaxel drug delivery systems aimed at improved patient outcomes: current status and challenges.

Authors:  Madhu S Surapaneni; Sudip K Das; Nandita G Das
Journal:  ISRN Pharmacol       Date:  2012-08-12

9.  A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect.

Authors:  Pei Kan; Chih-Wan Tsao; Ae-June Wang; Wu-Chou Su; Hsiang-Fa Liang
Journal:  J Drug Deliv       Date:  2010-10-11
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.